Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Leyden Labs licenses monoclonal antibody for influenza A and B from Janssen

By Brian Buntz | January 18, 2022

Leyden LabsJanssen (NYSE:JNJ) and Leyden Labs (Amsterdam) have signed a licensing agreement that gives the latter rights to develop CR9114, an antibody protecting against influenza A and B.

Leyden hopes to commercialize CR9114 as a nasal spray.

Under the terms of the deal, Janssen will get an upfront payment and could receive milestone payments tied to development- and sales-based milestones. Additionally, Janssen stands to receive tiered royalty payments if CR9114 is commercialized.

While COVID-19 continues to dominate the news landscape, influenza continues to kill roughly 20,000 people each year, according to CDC.

Preclinical data shows that CR9114 guards against influenza A and B.

“We believe that mucosal protection and treatment with CR9114 will provide people further control to protect themselves from seasonal flu,” said Koenraad Wiedhaup, CEO of Leyden Labs. “Importantly, CR9114 could also play a key role in preventing future flu pandemics.”

CR9114 traces its origins back to research from Janssen subsidiary Crucell Holland B.V. and The Scripps Research Institute related to human monoclonal antibodies with the potential of disabling influenza B viruses. At that time, the CR9114 antibodies protected mice against influenza A and B viruses.

Janssen announced that research initiative in 2012.

Founded in 2020, Leyden Labs focuses on developing mucosal-based therapies that can protect against infection from viral families.

In March 2021, the company received €40 million in Series A funding from GV (previously known as Google Ventures), F-Prime and Casdin Capital.


Filed Under: clinical trials, Drug Discovery, Drug Discovery and Development, Infectious Disease
Tagged With: CR9114, Janssen, Leyden Labs, nasal spray
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
Janssen
Janssen’s company group chairman dishes on growth strategy
Curebase
Curebase raises $40 million in Series B funding round 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50